The preventive effects of ondansetron on chemotherapy-induced nausea and vomiting in adult cancer patients: systematic review from ClinicalTrials.gov

被引：2

作者：

Ashour, Ahmed M. ^{[1
]}

机构：

[1] Umm Al Qura Univ, Coll Pharm, Pharmacol & Toxicol Dept, Mecca, Saudi Arabia

来源：

FRONTIERS IN PHARMACOLOGY | 2023年 / 14卷

关键词：

clinical trials; nausea; vomiting; ondansetron; patients;

D O I：

10.3389/fphar.2023.1310455

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Purpose: Cancer is a neoplastic transformation that affects tissue. Among the many complications associated with cancer treatment, managing the distressing side effects of chemotherapy-induced nausea and vomiting (CINV) is of main concern. Ondansetron is a selective serotonin 5-HT3 receptor antagonist that has emerged as an essential medication against CINV in adult cancer patients. Ondansetron efficacy and tolerability have made it a primary medication in CINV prophylaxis and treatment regimens. The study aims to offer a detailed overview of ondansetron's effectiveness, safety, and impact on patients' lives, ultimately contributing to the ongoing research to enhance the quality of cancer care.Methods: On 4 September 2023, a search was conducted of the ClinicalTrials.gov database using the search terms "cancer," "ondansetron," and "Zofran." Inclusion and exclusion criteria were defined to select relevant clinical trials. Included trials were completed with results and interventional studies that assessed the preventive effects of ondansetron on CINV in adult cancer patients.Results: A total of 23 clinical trials were identified, with only 13 of them focusing on investigating the preventive effects of ondansetron on CINV in adult cancer patients. The collective findings from these trials showed an effective management of CINV using ondansetron.Conclusion: Through a comprehensive overview of clinical trials, the use of ondansetron in adult cancer patients represents a significant improvement in CINV management.

引用

页数：6

共 27 条

[11] National library of medicine, 2019, Oral ondansetron versus transdermal granisetron (sancuso) for women with cervical, endometrial or vaginal cancer receiving pelvic chemoradiation, NCT01536392
[12] National library of medicine, 2015, Antiemetic therapy with or without olanzapine in preventing chemotherapy-induced nausea and vomiting in patients with cancer receiving highly emetogenic chemotherapy. NCT02116530
[13] National library of medicine, 2017, Emend and ondansetron compared to ondansetron alone to prevent CINV in glioma patients receiving temozolomide, NCT01450826
[14] National library of medicine, 2017, Dexamethasone and ondansetron hydrochloride or palonosetron hydrochloride in preventing nausea and vomiting in patients receiving doxorubicin hydrochloride and cyclophosphamide for early stage breast cancer. NCT00343863
[15] National library of medicine, 2011, Aprepitant's effect on drug metabolism in multi-day combination (CHOP/R-CHOP) chemotherapy regimen in lymphoma patients, NCT00651755
[16] National library of medicine, 2009, Aprepitant in preventing nausea and vomiting in patients who are undergoing a stem cell transplant. NCT00248547
[17] National library of medicine, 2009, Palonosetron versus ondansetron for the prevention of nausea and vomiting. NCT01031498
[18] National library of medicine, 2010, Ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis after receiving cisplatin. NCT01093690
[19] Rao Kamakshi V, 2012, Am Health Drug Benefits, V5, P232
[20] 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
Roila, F.
Molassiotis, A.
Herrstedt, J.
Aapro, M.
Gralla, R. J.
Bruera, E.
Clark-Snow, R. A.
Dupuis, L. L.
Einhorn, L. H.
Feyer, P.
Hesketh, P. J.
Jordan, K.
Olver, I.
Rapoport, B. L.
Roscoe, J.
Ruhlmann, C. H.
Walsh, D.
Warr, D.
van der Wetering, M.
[J]. ANNALS OF ONCOLOGY, 2016, 27 : v119 - v133

← 1 2 3 →